Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn's flagship product. Burnam, a self-taught regulatory and formulation expert, secured Turn's first three FDA clearances solo before assembling a skilled team.
$X,XXX,XXX
INVESTED SO FAR
The Future of Dermatology Innovation
The Future of Dermatology Innovation
Turn Therapeutics combines three FDA clearances1, $70 million in licensing agreements, and a proven formula used in 200,000+ real-world treatments with zero FDA-reported adverse events. Backed by a $75 million equity agreement2 and targeting rapidly growing markets, we offer a unique opportunity to invest in a company poised for significant scale.
This Reg A+ offering is made available through StartEngine Primary, LLC, a member of FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
1The company's formula (GX-03/Hexagen/Atopx) has received 510K marketing approval as a medical device indicated for the management of symptoms related to atopic dermatitis/eczema. The formula has not received approval as a drug
for the treatment of eczema or onychomycosis.
2This equity agreement provides Turn Therapeutics with up to $75M in capital over a 36-month period in the event Turn Therapeutics publicly lists its stock. Public listing may never occur.
Join our email list
Thank you! Your submission has been received!
By clicking "Sign Up", you consent to receive marketing text messages (e.g. promos, cart reminders) from StartEngine Crowdfunding, Inc. at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms
a story of grit
CEO's
Self-Cure
to Treatment Innovation
Facing recurring, life-threatening infections and over 20 failed surgeries, our founder Bradley Burnam refused to give up. With no medical background and limited resources, he developed Hexagen—a groundbreaking formula that not only saved his life but transformed wound and skin care.
Hexagen is FDA-cleared for the management of advanced wounds and burns, including diabetic ulcers and post-surgical wounds. Laboratory testing has demonstrated its effectiveness in reducing harmful bacteria, including MRSA, by over 99%, while being non-damaging to tissue, non-irritating, and non-sensitizing to skin. Additionally, independent human skin testing has confirmed it as hypoallergenic.This formula is also FDA-cleared for managing eczema, diaper rash, and radiation burns. Hexagen is trusted by healthcare professionals for its safety profile and demonstrated effectiveness in wound and skin care.
200K+ Human Applications,
Zero Adverse Events Reported
proven traction. tangible results.
*Commercial License agreement amount represents the total expected value upon full performance of the agreement.
Millions of Patients Need
Better Treatment Solutions
traditional treatment falls short
Turn Therapeutics’ flagship formula, Hexagen, has been shown in clinical studies to inhibit the immune signals that lead to eczema, manage diaper rash, heal radiation burn, and even kill MRSA.
Eczema affects 31 million Americans.
Toenail fungus impacts 10 percent
of the population.
of the population.
Traditional therapies, like steroids,
injectables, and outdated anti-fungal topicals
injectables, and outdated anti-fungal topicals
- Fail to address root causes and don’t deliver consistent results
- Leave patients frustrated and underserved.
How It Works
Hexagen is designed to help manage eczema symptoms by utilizing a proprietary liquid-in-oil suspension process called PermaFusion™. This innovative approach allows for a non-steroidal, non-systemic formula that incorporates trusted ingredients in a unique way. While individual results may vary, Hexagen aims to support skin health without the use of steroids.
The Hexagen formula has no steroids, is non-systemic, and employs trusted ingredients in a proprietary way.
*The above graphic is a computer generated visual representation
Impacting a Combined Market of $45M
Turn Therapeutics is strategically aiming at two rapidly growing markets:
Turn Therapeutics is positioned to capitalize on this growing demand due to its extensive human data, proven formula, and high market demand.
.png)
Millions of Patients Need
Better Treatment Solutions
$70M Commercial License Deal
With Mimedx
We've secured a $70 million license deal with Mimedx, an organization that provides non-dilutive funding for drug development.
$70M Commercial License Deal
With Mimedx
We've secured a license deal worth up to $70 million with Mimedx, an organization that provides non-dilutive funding for drug development.
Commercial License agreement amount represents the total expected value upon full performance of the agreement.
Leadership Built on
Innovation and Execution
Turn Therapeutics has earned the confidence of well-known investors, including executives from Eli Lilly, Sanofi, and Arch Ventures.
Our company is guided by shareholders, board members, and industry professionals with extensive experience in pharmaceutical transactions. While every investment carries risks, our leadership team has navigated similar ventures successfully in the past.
.png)
Bradley Burnham
Chief Executive Officer, Board Member & Founder
Dr. Neil Ghodadra, M.D.
Chief Medical Officer & Board Member
Dr. Neil Ghodadra, Board Certified Orthopedic Surgeon, joined Turn in Q3 2017. Renowned for surgical skill and orthopedic research, he graduated Magna Cum Laude from Duke University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery.
Abraham Chesed
Board Member
Abraham (Avi) Chesed, an investor and entrepreneur with an aptitude for building and structuring brands, is a lifelong technologist, philanthropist, and mentor. He has founded and operated companies since graduating from the USC Marshall School of Business in 2003. Avi's thorough and professional focus has yielded substantial returns across multiple industries, recently in technology-focused startups. Avi has been a member of over a dozen boards and sits on five.
Andrew Gengos
Board Member/Advisor
Andrew Gengos is a seasoned finance & strategy exec with 30+ years in life sciences and biotech. Former CBO at Cyteir Therapeutics, he led the company to go public. Andrew served as CEO at ImmunoCellular & Neuraltus, providing strategic direction in oncology & neurodegenerative disease. He’s held CFO/CBO roles at AOBiome, COO at Synlogic, & VP at Amgen.
Arthur Golden
Advisor / Board Observer
Arthur Golden is a 41-year partner of Davis Polk’s M&A practice, former co-chair of the dept. & 9-year member of the firm's Management Committee. As Emerson Electric's senior independent board member, he chairs the Finance Committee. Known for multinational acquisitions and biopharma expertise, Arthur is also the Chair of Rensselaer Polytechnic Institute's Board of Trustees.
Eric Luo, Ph.D.
Regulatory Affairs
Eric Luo, Ph.D., a transdermal drug delivery expert, enhances product efficacy by studying polymer properties and modifying materials. Formerly with Schering-Plough and Novartis, Dr. Luo holds a Ph.D. in Materials Science and Engineering from the University of Florida and an M.S. in Chemical Engineering from the University of Nebraska.
Conoon Kim
IT & Infrastructure
Conoon Kim, a seasoned technology expert, oversees Turn's digital communications, branding, and platform development. With over a decade of experience in IT, digital marketing, and project management, he plays a pivotal role in managing website development, social media, video production, and digital strategy.
Martin Dewhurst
Advisor
Martin Dewhurst spent 30 years with McKinsey, where his primary focus was life sciences, covering global biopharma, medtech, genetics, and consumer health. He led McKinsey’s life sciences practice for 7 years and co-founded and led the McKinsey Health Institute, a non-profit entity focused on addressing fundamental health challenges.
Martin Bott
Advisor
During his 31 year career at Lilly, Martin Bott held a series of leadership roles with growing responsibilities mainly in finance, business development, and project management. Notably, he served as the CFO of Lilly Diabetes, CFO of Global Manufacturing, led the Corporate Finance and Investment Banking group, and led the strategic review and resulting IPO and spin off of Lilly’s animal health division – Elanco Animal Health.
Jeffrey Bunder
Advisor
Jeff is a seasoned financial and investment professional with extensive experience in private equity, corporate finance, and transaction advisory. He spent over two decades at Ernst & Young (EY), where he served as the Global Private Equity Leader, advising some of the world’s largest private equity firms on deal structuring, fundraising, and portfolio optimization.
Kent Kester, M.D
Advisor
Kent Kester, M.D., is currently Executive Director of Vaccine Research and Development at Center for Epidemic Preparedness Institute (CEPI), where he directs a $1B research and development budget. Prior to CEPI, Dr. Kester served as Vice President, Translational Medicine, at International AIDS Vaccine Initiative (IAVI). Before IAVI, Dr. Kester was Vice President and Head, Translational Science and Biomarkers at Sanofi Pasteur, the vaccine business unit of the Sanofi Group. Prior to Sanofi, he had a 24-year career in the U.S. Army, where he worked extensively in clinical vaccine development at the Walter Reed Army Institute of Research, an institution he later led as its Commander.
Peter Gould
Advisor
Peter Gould is a Managing Director at J.P. Morgan Private Bank, bringing over 30 years of banking experience spanning asset-based lending, commercial banking, investment banking, and private banking. His specific expertise lies in complex credit structures, capital markets, and strategic financial solutions.
Bradley Burnam
Chief Executive Officer, Board Member & Founder
Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn's flagship product. Burnam, a self-taught regulatory and formulation expert, secured Turn's first three FDA clearances solo before assembling a skilled team.
Dr. Neil Ghodadra, M.D.
Chief Medical Officer & Board Member
Dr. Neil Ghodadra, Board Certified Orthopedic Surgeon, joined Turn in Q3 2017. Renowned for surgical skill and orthopedic research, he graduated Magna Cum Laude from Duke University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery.
Abraham Chesed
Board Member
Abraham (Avi) Chesed, an investor and entrepreneur with an aptitude for building and structuring brands, is a lifelong technologist, philanthropist, and mentor. He has founded and operated companies since graduating from the USC Marshall School of Business in 2003. Avi's thorough and professional focus has yielded substantial returns across multiple industries, recently in technology-focused startups. Avi has been a member of over a dozen boards and sits on five.
Andrew Gengos
Board Member/Advisor
Andrew Gengos is a seasoned finance & strategy exec with 30+ years in life sciences and biotech. Former CBO at Cyteir Therapeutics, he led the company to go public. Andrew served as CEO at ImmunoCellular & Neuraltus, providing strategic direction in oncology & neurodegenerative disease. He’s held CFO/CBO roles at AOBiome, COO at Synlogic, & VP at Amgen.
Arthur Golden
Board Member/Advisor
Arthur Golden is a 41-year partner of Davis Polk’s M&A practice, former co-chair of the dept. & 9-year member of the firm's Management Committee. As Emerson Electric's senior independent board member, he chairs the Finance Committee. Known for multinational acquisitions and biopharma expertise, Arthur is also the Chair of Rensselaer Polytechnic Institute's Board of Trustees.
Eric Luo, Ph.D.
Regulatory Affairs
Eric Luo, Ph.D., a transdermal drug delivery expert, enhances product efficacy by studying polymer properties and modifying materials. Formerly with Schering-Plough and Novartis, Dr. Luo holds a Ph.D. in Materials Science and Engineering from the University of Florida and an M.S. in Chemical Engineering from the University of Nebraska.
Conoon Kim
IT & Infrastructure
Conoon Kim, a seasoned technology expert, oversees Turn's digital communications, branding, and platform development. With over a decade of experience in IT, digital marketing, and project management, he plays a pivotal role in managing website development, social media, video production, and digital strategy.
Martin Dewhurst
Advisor
Martin Dewhurst spent 30 years with McKinsey, where his primary focus was life sciences, covering global biopharma, medtech, genetics, and consumer health. He led McKinsey’s life sciences practice for 7 years and co-founded and led the McKinsey Health Institute, a non-profit entity focused on addressing fundamental health challenges.
Martin Bott
Advisor
During his 31 year career at Lilly, Martin Bott held a series of leadership roles with growing responsibilities mainly in finance, business development, and project management. Notably, he served as the CFO of Lilly Diabetes, CFO of Global Manufacturing, led the Corporate Finance and Investment Banking group, and led the strategic review and resulting IPO and spin off of Lilly’s animal health division – Elanco Animal Health.
Jeffrey Bunder
Advisor
Jeff is a seasoned financial and investment professional with extensive experience in private equity, corporate finance, and transaction advisory. He spent over two decades at Ernst & Young (EY), where he served as the Global Private Equity Leader, advising some of the world’s largest private equity firms on deal structuring, fundraising, and portfolio optimization.
Kent Kester, M.D
Advisor
Kent Kester, M.D., is currently Executive Director of Vaccine Research and Development at Center for Epidemic Preparedness Institute (CEPI), where he directs a $1B research and development budget. Prior to CEPI, Dr. Kester served as Vice President, Translational Medicine, at International AIDS Vaccine Initiative (IAVI). Before IAVI, Dr. Kester was Vice President and Head, Translational Science and Biomarkers at Sanofi Pasteur, the vaccine business unit of the Sanofi Group. Prior to Sanofi, he had a 24-year career in the U.S. Army, where he worked extensively in clinical vaccine development at the Walter Reed Army Institute of Research, an institution he later led as its Commander.
Peter Gould
Advisor
Peter Gould is a Managing Director at J.P. Morgan Private Bank, bringing over 30 years of banking experience spanning asset-based lending, commercial banking, investment banking, and private banking. His specific expertise lies in complex credit structures, capital markets, and strategic financial solutions.
Invest in the
Future of Skin
Care Innovation
proven therapies.
high growth markets.
Turn Therapeutics combines a strong regulatory track record, proprietary technology, and real-world success to deliver safer, more effective care for millions of underserved patients. Your investment can help fund clinical trials, expand partnerships, and drive innovations that aim to redefine skin care.
Invest today and join us in transforming the future of dermatology.
AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT CAN BE FOUND HERE.
CROWDCHECK VERIFIED REPORT CAN BE FOUND HERE.
THIS WEBPAGE MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT”, “CAN” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
CROWDCHECK VERIFIED REPORT CAN BE FOUND HERE.
THIS WEBPAGE MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT”, “CAN” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
Terms
Overview
Price per share
$11.26
Deadline
June 27th at 11:59 PM PT
Valuation
$162.56M
Funding goal
$990.9 - $15M
Breakdown
Min Investment
$990.88
Max investment
$14,999,997.70
Min number of shares offered
88
Max number of shares offered
1,332,148
Offering type
Equity
Common Stock
Class 1 Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
Exclusive Investor Perks
Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Hylio.
Venture Club
Venture Club Members earn 10% bonus on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Turn Therapeutics.
Loyalty Bonus | 3% Bonus Shares
Investors who have previously, in a prior offering, invested in the Company, receive 3% Bonus Shares (the “Loyalty Bonus”), in addition to any StartEngine Venture Club Bonus shares, or Amount-Based Bonus shares, to which they are entitled to receive.
Bonus shares for this offering are capped at 20%
Tier 1
Tier 2
Tier 3
The 10% StartEngine Venture Club Bonus
GLOBAL HEALTH SOLUTIONS, INC. , dba Turn Therapeutics will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Venture Club.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $11.26 / share, you will receive 110 shares of Common Stock, meaning you’ll own 110 shares for $1126. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor’s eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Venture Club bonus and the Loyalty Bonus in addition to the aforementioned bonus, provided that the maximum bonus shares granted to any investor shall not be greater than 20%.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.
Voting Proxy
(a) The Subscriber hereby appoints the Chief Executive Officer of the Company (the “Chief Executive Officer”), or his or her successor as Chief Executive Officer, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution to assign this proxy to any officer or director, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the Chief Executive Officer determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the Chief Executive Officer for the accomplishment of the foregoing. See Offering Circular for complete information.
Venture Club
Venture Club Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Turn Therapeutics.
Loyalty Bonus | 3% Bonus Shares
Investors who have previously, in a prior offering, invested in the Company, receive 3% Bonus Shares (the “Loyalty Bonus”), in addition to any StartEngine Venture Club Bonus shares, or Amount-Based Bonus shares, to which they are entitled to receive.
Bonus shares for this offering are capped at 20%
The 10% StartEngine Venture Club Bonus
GLOBAL HEALTH SOLUTIONS, INC. , dba Turn Therapeutics will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Venture Club.This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $11.26 / share, you will receive 110 shares of Common Stock, meaning you’ll own 110 shares for $1126. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.This 10% Bonus is only valid during the investor’s eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Venture Club bonus and the Loyalty Bonus in addition to the aforementioned bonus, provided that the maximum bonus shares granted to any investor shall not be greater than 20%.*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.
Voting Proxy
(a) The Subscriber hereby appoints the Chief Executive Officer of the Company (the “Chief Executive Officer”), or his or her successor as Chief Executive Officer, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution to assign this proxy to any officer or director, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the Chief Executive Officer determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the Chief Executive Officer for the accomplishment of the foregoing. See Offering Circular for complete information.
Loyalty Bonus | 3% Bonus Shares
Investors who have previously, in a prior offering, invested in the Company, receive 3% Bonus Shares (the “Loyalty Bonus”), in addition to any StartEngine Venture Club Bonus shares, or Amount-Based Bonus shares, to which they are entitled to receive.
Bonus shares for this offering are capped at 20%
The 10% StartEngine Venture Club Bonus
GLOBAL HEALTH SOLUTIONS, INC. , dba Turn Therapeutics will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Venture Club.This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $11.26 / share, you will receive 110 shares of Common Stock, meaning you’ll own 110 shares for $1126. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.This 10% Bonus is only valid during the investor’s eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Venture Club bonus and the Loyalty Bonus in addition to the aforementioned bonus, provided that the maximum bonus shares granted to any investor shall not be greater than 20%.*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.
Voting Proxy
(a) The Subscriber hereby appoints the Chief Executive Officer of the Company (the “Chief Executive Officer”), or his or her successor as Chief Executive Officer, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution to assign this proxy to any officer or director, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the Chief Executive Officer determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the Chief Executive Officer for the accomplishment of the foregoing. See Offering Circular for complete information.
Join the Discussion
Please check your email for the One Time Password. Didn't Receive an email? click Here
Your investment account has some outstanding AML/KYC issues that need your attention. Please help us resolve these by clicking Here and addressing the issues listed in your account.
Your investment account has some outstanding AML/KYC issues that need your attention. Please help us resolve these by clicking Here and addressing the issues listed in your account.
We'll email you once we are done reviewing your account. If it's been longer than 5 days since you addressed all issues, please email us at contact@startengine.com.
The community wants to hear your thoughts. Create an investment account HERE to join the discussion.
Your investment account has some outstanding AML/KYC issues that need your attention. Please help us resolve these by clicking HERE and addressing the issues listed in your account.
Join our email list
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By clicking "Sign Up", you consent to receive marketing text messages (e.g. promos, cart reminders) from StartEngine Crowdfunding, Inc. at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms
Dismiss
Bradley Burnham
Chief Executive Officer, Board Member & Founder
Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn's flagship product. Burnam, a self-taught regulatory and formulation expert, secured Turn's first three FDA clearances solo before assembling a skilled team.
Dr. Neil Ghodadra, M.D.
Chief Medical Officer & Board Member
Dr. Neil Ghodadra, Board Certified Orthopedic Surgeon, joined Turn in Q3 2017. Renowned for surgical skill and orthopedic research, he graduated Magna Cum Laude from Duke University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery.
Abraham Chesed
Board Member
Abraham (Avi) Chesed, an investor and entrepreneur with an aptitude for building and structuring brands, is a lifelong technologist, philanthropist, and mentor. He has founded and operated companies since graduating from the USC Marshall School of Business in 2003. Avi's thorough and professional focus has yielded substantial returns across multiple industries, recently in technology-focused startups. Avi has been a member of over a dozen boards and sits on five.
Andrew Gengos
Board Member/Advisor
Andrew Gengos is a seasoned finance & strategy exec with 30+ years in life sciences and biotech. Former CBO at Cyteir Therapeutics, he led the company to go public. Andrew served as CEO at ImmunoCellular & Neuraltus, providing strategic direction in oncology & neurodegenerative disease. He’s held CFO/CBO roles at AOBiome, COO at Synlogic, & VP at Amgen.
Arthur Golden
Advisor / Board Observer
Arthur Golden is a 41-year partner of Davis Polk’s M&A practice, former co-chair of the dept. & 9-year member of the firm's Management Committee. As Emerson Electric's senior independent board member, he chairs the Finance Committee. Known for multinational acquisitions and biopharma expertise, Arthur is also the Chair of Rensselaer Polytechnic Institute's Board of Trustees.
Eric Luo, Ph.D.
Regulatory Affairs
Eric Luo, Ph.D., a transdermal drug delivery expert, enhances product efficacy by studying polymer properties and modifying materials. Formerly with Schering-Plough and Novartis, Dr. Luo holds a Ph.D. in Materials Science and Engineering from the University of Florida and an M.S. in Chemical Engineering from the University of Nebraska.
Conoon Kim
IT & Infrastructure
Conoon Kim, a seasoned technology expert, oversees Turn's digital communications, branding, and platform development. With over a decade of experience in IT, digital marketing, and project management, he plays a pivotal role in managing website development, social media, video production, and digital strategy.
Martin Dewhurst
Advisor
Martin Dewhurst spent 30 years with McKinsey, where his primary focus was life sciences, covering global biopharma, medtech, genetics, and consumer health. He led McKinsey’s life sciences practice for 7 years and co-founded and led the McKinsey Health Institute, a non-profit entity focused on addressing fundamental health challenges.
Martin Bott
Advisor
During his 31 year career at Lilly, Martin Bott held a series of leadership roles with growing responsibilities mainly in finance, business development, and project management. Notably, he served as the CFO of Lilly Diabetes, CFO of Global Manufacturing, led the Corporate Finance and Investment Banking group, and led the strategic review and resulting IPO and spin off of Lilly’s animal health division – Elanco Animal Health.
Jeffrey Bunder
Advisor
Jeff is a seasoned financial and investment professional with extensive experience in private equity, corporate finance, and transaction advisory. He spent over two decades at Ernst & Young (EY), where he served as the Global Private Equity Leader, advising some of the world’s largest private equity firms on deal structuring, fundraising, and portfolio optimization.
Kent Kester, M.D
Advisor
Kent Kester, M.D., is currently Executive Director of Vaccine Research and Development at Center for Epidemic Preparedness Institute (CEPI), where he directs a $1B research and development budget. Prior to CEPI, Dr. Kester served as Vice President, Translational Medicine, at International AIDS Vaccine Initiative (IAVI). Before IAVI, Dr. Kester was Vice President and Head, Translational Science and Biomarkers at Sanofi Pasteur, the vaccine business unit of the Sanofi Group. Prior to Sanofi, he had a 24-year career in the U.S. Army, where he worked extensively in clinical vaccine development at the Walter Reed Army Institute of Research, an institution he later led as its Commander.
Peter Gould
Advisor
Peter Gould is a Managing Director at J.P. Morgan Private Bank, bringing over 30 years of banking experience spanning asset-based lending, commercial banking, investment banking, and private banking. His specific expertise lies in complex credit structures, capital markets, and strategic financial solutions.